Sigma-Aldrich To Buy BioReliance Holdings
BioReliance Holdings will be sold by Avista Partners to Sigma-Aldrich. The price is $350 million. The acquirer said BioReliance provides critical services that include biologic, specialized toxicology and animal health testing to pharmaceutical, biopharmaceutical, diagnostics, and other life science customers…
BioReliance Holdings will be sold by Avista Partners to Sigma-Aldrich. The price is $350 million. The acquirer said
BioReliance provides critical services that include biologic, specialized toxicology and animal health testing to pharmaceutical, biopharmaceutical, diagnostics, and other life science customers worldwide. BioReliance’s service offering helps facilitate biological drug development, manufacturing and commercialization activities.
Sigma added
BioReliance generated revenues of approximately $110 million in the year ended December 31, 2010 with double-digit growth expected in 2011. The acquisition is expected to be modestly accretive to Sigma-Aldrich’s diluted EPS in 2012 and enhance its already strong free cash flow.
Contact [email protected] for any questions or corrections.





